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Background: Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of
mitosis and programmed cell death. YM155, a novel molecular targeted agent, suppresses survivin, which is
overexpressed in many tumor types. The aim of this study was to determine the antitumor activity of YM155 in
SK-NEP-1 cells.
Methods: SK-NEP-1 cell growth in vitro and in vivo was assessed by MTT and nude mice experiments. Annexin V/
propidium iodide staining followed by flow cytometric analysis was used to detect apoptosis in cell culture. Then
gene expression profile of tumor cells treated with YM155 was analyzed with real-time PCR arrays. We then
analyzed the expression data with MEV (Multi Experiment View) cluster software. Datasets representing genes with
altered expression profile derived from cluster analyses were imported into the Ingenuity Pathway Analysis tool.
Results: YM155 treatment resulted in inhibition of cell proliferation of SK-NEP-1cells in a dose-dependent manner.
Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1
cells. YM155 significantly inhibited growth of SK-NEP-1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm3; YM155 10 mg/
kg: 0.95 ± 0.55 cm3) compared to DMSO group (DMSO: 3.70 ± 2.4 cm3) or PBS group cells (PBS: 3.78 ± 2.20 cm3,
ANOVA P < 0.01). YM155 treatment decreased weight of tumors (YM155 5 mg/kg: 1.05 ± 0.24 g; YM155 10 mg/kg:
0.72 ± 0.17 g) compared to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group cells (PBS: 2.36 ± 0.43 g, ANOVA P <
0.01). Real-time PCR array analysis showed between Test group and control group there are 32 genes significantly
up-regulated and 54 genes were significantly down-regulated after YM155 treatment. Ingenuity pathway analysis
(IPA) showed cell death was the highest rated network with 65 focus molecules and the significance score of 44.
The IPA analysis also groups the differentially expressed genes into biological mechanisms that are related to cell
death, cellular function maintenance, cell morphology, carbohydrate metabolism and cellular growth and
proliferation. Death receptor signaling (3.87E-19), TNFR1 signaling, induction of apoptosis by HIV1, apoptosis
signaling and molecular mechanisms of cancer came out to be the top four most significant pathways. IPA analysis
also showed top molecules up-regulated were BBC3, BIRC3, BIRC8, BNIP1, CASP7, CASP9, CD5, CDKN1A, CEBPG and
COL4A3, top molecules down-regulated were ZNF443, UTP11L, TP73, TNFSF10, TNFRSF1B, TNFRSF25, TIAF1, STK17A,
SST and SPP1, upstream regulator were NR3C1, TP53, dexamethasone , TNF and Akt.
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Conclusions: The present study demonstrates that YM155 treatment resulted in apoptosis and inhibition of cell
proliferation of SK-NEP-1cells. YM155 had significant role and little side effect in the treatment of SK-NEP-1
xenograft tumors. Real-time PCR array analysis firstly showed expression profile of genes dyes-regulated after YM155
treatment. IPA analysis also represents new molecule mechanism of YM155 treatment, such as NR3C1 and
dexamethasone may be new target of YM155. And our results may provide new clues of molecular mechanism of
apoptosis induced by YM155.
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Wilms tumor (WT) is the most common malignant neo-
plasm of the urinary tract in children [1]. Although it is
curable with long-term survival, the combination of sur-
gery, chemotherapy and often radiotherapy in some
cases results in severe complications in adulthood [2].
Therefore, novel therapeutic strategies that would de-
crease treatment burden and improve outcome for high
risk patients are required. We evaluated the efficacy of
YM155, an inhibitor of survivin, to inhibit Wilms tumor
development in xenografts models.
Overexpressed survivin can be detected in virtually
every human tumor, but undetectable or present at very
low levels in most normal adult tissues [3-5]. A ‘tumor-
specific’ expression of survivin is predominantly dictated
at the level of transcription, and that survivin gene ex-
pression may be globally ‘deregulated’ in tumors, in vivo
[4,6,7]. Accordingly, survivin promoter activity is basic-
ally silent in normal cells, but strongly activated in
tumor cells, and this occurs independently of cellular
heterogeneity, mitotic status, or genetic makeup. The
differential expression of the survivin gene in normal
versus tumor cells is so dramatic that therapeutic strat-
egies to drive tumor-specific expression of suicidal genes
under the control of the survivin promoter have now
advanced to preclinical stages in a number of settings
[3,5-9].
YM155, a novel small-molecule survivin suppressant,
has been shown to suppress survivin with little effect on
expression levels of other IAP family or Bcl-2 related
proteins [10]. YM155 has been demonstrated antitumor
activity, with survivin suppression and tumor cell apop-
tosis, in various human cancer models [6,8,10-17]. Survi-
vin is the smallest member of the Inhibitor of Apoptosis
(IAP) gene family. Originally described as cell survival
factors that target caspase, we now know that IAPs have
a much broader portfolio of functions, encompassing
signaling pathways, cell division, metabolism and adapta-
tion to unfavorable environments. Survivin embodies
this multifunctional diversity, and compelling data accu-
mulated over a decade have elucidated many of its es-
sential roles as a regulator of mitosis [17], a broad
cytoprotective factor [18,19], and an effector of cellularadaptation to stress [20,21]. These disparate functions
rely on hosts of regulated interactions that involve survi-
vin and multiple protein partners, including tubulin
[22,23] and various chromosomal passenger proteins in
the control of mitosis, other IAP family members to
counteract apoptosis, and Heat Shock Proteins in the
modulation of the cellular stress response. These ‘survi-
vin networks’ are dramatically exploited in cancer, and
survivin is unanimously viewed as one of the most
prominent cancer genes.
In the present study, the antitumor effect of YM155
have been evaluated in human SK-NEP-1 Wilms tumor
cells and xenograft models to further characterize its
preclinical efficacy, and the molecular mechanism was
exploited with real-time PCR arrays.
Methods
Cell and culture conditions
SK-NEP-1 Human kidney (Wilm's Tumor) cell line
obtained from the American Type Culture Collection
(ATCC) was maintained in the Maccyo’5 (Life Technolo-
gies Inc., Gaithersburg, MD, USA) supplemented with
20% heat-inactivated fetal bovine serum (Invitrogen Co.,
NY, USA) in a humidified incubator with 5% CO2 at 37°C.
YM155 (Cat: S1130 Selleck Chemicals, West Paterson, NJ,
USA) was dissolved in DMSO (Cat: D4540 Sigma–
Aldrich, St. Louis, MO, USA)
Cell proliferation
Sk-NEP-1 cells (2×104) were seeded in 96-well plates
overnight and incubated with DMSO, 1 nM YM155, or
increasing concentrations of YM155 (0.005, 0.01, 0.02,
0.04, 0.08, 0.16, 0.32, 0.64 or 1.28 μM) for 24 hours. The
volume of DMSO added to the vehicle treated wells was
the same as that added to the drug treated wells. Each
drug concentration was performed in four replicate
wells. 20uLMTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) solution (5 mg/ml) was
added to each well and incubated at 37°C for a further
4 hours. Then 200 uL of DMSO was added to each well
after the medium was removed. The optical density
(OD) values were measured at 490 nm on a scanning
multi-well spectrophotometer (BioRad Model 550,
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survival rate of remained cells was calculated from the
absorbance values. Cell proliferation was calculated as a
percentage of the DMSO- treated control wells with
IC50 values derived after plotting proliferation values on
a logarithmic curve.
Cell cycle analysis
Cells were collected and washed with PBS for 5 minutes
by centrifugation at 125 × g. Cells were fixed with paraf-
ormaldehyde and transparented with 0.5% Triton X-100.
Then cells were resuspended in a staining solution con-
taining 1.5 μmol/L propidium iodide (P4170, Sigma–
Aldrich, St. Louis, MO, USA) and 25 μg/ml RNase A
and incubated for 30 minutes in 37°C. The samples
(10000 cells) were analyzed by fluorescence-activated
cell sorting with a Beckman Gallios™ Flow Cytometer.
Apoptosis assay
Apoptosis assay was according to the manual operation
of BD Annexin V Staining Kit (Cat: 556420, BD Bios-
ciences, Franklin Lakes, NJ USA). Briefly, wash cells
twice with cold PBS and then resuspend cells in 1×Bind-
ing Buffer at a concentration of ~1 ×106 cells/ml. Trans-
fer 100 μl of the solution (~1×105 cells) to a 5 ml
culture tube. Add Annexin V and PI 5 μl/test. Gently
mix the cells and incubate for 15 min at RT in the dark.
Add 400 μl of 1×Binding Buffer to each tube. Analyze by
flow cytometry as soon as possible (within 1 hour).
Western blot analysis
For western blot analysis, cellular proteins were
extracted in 40 mM Tris–HCl (pH 7.4) containing
150 mM NaCl and 1% (v/v) Triton X-100, supplemented
with a cocktail of protease inhibitors. Equal amounts of
protein were resolved on 12% SDS-PAGE gels, and then
transferred to a PVDF membrane (Millipore, Bedford,
MA). Blots were blocked and then probed with anti-
bodies against Caspase 3 (1:1000,
Cell Signaling Technology, Inc. Danvers, MA),
GAPDH (1:5000, Sigma, St. Louis, MO). After washing,
the blots were incubated with horseradish peroxidase-
conjugated secondary antibodies and visualized by
enhanced chemiluminescence kit (Pierce, Rockford, IL).
Protein bands were visualized after exposure of the
membrane to Kodak X-ray film.
Xenograft assays the treatment effect of YM155 in nude
mice
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of Soochow university(Permit Number: 2011-10-21). All surgery was per-
formed under sodium pentobarbital anesthesia, and all
efforts were made to minimize suffering. Female nu/nu
mice, aged 4–6 weeks, obtained from the Jackson La-
boratory (Vitalriver, China), were kept in Class 10000
Clean Room at the Laboratory Animal Center of Soo-
chow University (http://dwzx.suda.edu.cn/pages/index.
aspx.) SK-NEP-1 cells were subcutaneously injected into
five nude mice every group. 10 days after injection, mice
were treated with PBS, DMSO, YM155 5 mg/kg and
10 mg/kg dose. During the next six weeks these mice
were examined for subcutaneous tumor growth. The
tumor volumes were calculated according to the follow-
ing formula: volume = length × width2/2. After the last
treatment, the mice were killed and the tumor weight
was measured.
Real-time PCR array analysis
For RNA extraction, cells were immediately submerged
in 2 ml Trizol (Invitrogen Co., NY, USA), stored at −80°C
until further processed. A volume of 1 ml of each sample
was spun at 4°C for 15 min at 12,000 g to remove debris
and DNA, 1 ml of supernatant was mixed with 200 ul
chloroform, shaken for 15 seconds, incubated at Room
Temperature for 2–3 minutes and spun for 10 minutes at
12,000 g at 4°C. RNA was precipitated by adding 500 ul of
the aqueous phase to an equal volume of isopropanol and
spun at 14,000 g at 4°C for 10 minutes. RNA was washed
with 75% ethanol, spun at 14,000 g at 4°C for 10 minutes,
dried and resuspended in 40 ul DEPC-treated H2O . The
final RNA concentration was determined using a spectro-
photometer (Nanodrop 2000) and the purity was assessed
by agarose gel electrophoresis. CDNA synthesis was per-
formed on 4 ug of RNA in a 10 ul sample volume using
SuperScript II reverse transcriptase (Invitrogen Co., NY,
USA) as recommended by the manufacturer. The RNA
was incubated with 0.5 ug of oligo(dT)12–18mers primers
(Invitrogen Co., NY, USA) for 7 minutes at 70°C and then
transferred onto ice. Then, 9 ul of a master mix containing
4 ul of SuperScript II buffer, 2 ul of 0.1 M DTT, and 1 ul
each of dNTPs stock (10 mM), Rnasin (40 UI) and Super-
Script II were added to the RNA sample, spun and incu-
bated at 42°C for 60 min followed by 5 min at 70°C to
inactivate the enzyme. CDNA was stored at −20°C. Real-
time PCR array (SABioscience Human Apoptosis PCR
Array PAHS-3012) analysis was performed in a total
volume of 20 ul including 2ul of cDNA, primers (0.2 mM
each) and 10 ul of SYBR Green mix (Roche Co., Basel,
Switzerland.). Reactions were run on an Light cycler
480 using the universal thermal cycling parameters
(95°C 5 min, 45 cycles of 10 sec at 95°C, 20 sec at 60°C
and 15 sec at 72°C; melting curve: 10 sec at 95°C, 60 sec at
60°C and continues melting). Results were obtained using
the sequence detection software Light cycler 480 and
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curves were acquired for quality control purposes. For
gene expression quantification, we used the comparative
Ct method. First, gene expression levels for each sample
were normalized to the expression level of the housekeep-
ing gene encoding Glyceraldehydes 3-phosphate dehydro-
genase (GAPDH) within a given sample (−ΔCt); the
relative expression of each gene was calculated with106
*Log2(−ΔCt ).The difference between the YM155 treat-
ment samples compared to the control samples was used
to determine the106 *Log2(−ΔCt ). Statistical significance
of the gene expression difference between the YM155
treatment and the control samples was calculated with the
T-test using SPSS 11.5 software.
Ingenuity pathway analysis (IPA)
Datasets representing genes with altered expression
profile derived from Real-time PCR array analyses were
imported into the Ingenuity Pathway Analysis Tool
(IPA Tool; Ingenuity H Systems, Redwood City, CA,
USA; http://www.ingenuity.com). In IPA, differentially
expressed genes are mapped to genetic networks avail-
able in the Ingenuity database and then ranked by
score. The basis of the IPA program consists of the In-
genuity Pathway Knowledge Base (IPKB) which is
derived from known functions and interactions of
genes published in the literature. Thus, the IPA Tool
allows the identification of biological networks, global
functions and functional pathways of a particular data-
set. The program also gives the significance value of
the genes, the other genes with which it interacts, and
how the products of the genes directly or indirectly act
on each other, including those not involved in the
microarray analysis. The networks created are ranked
depending on the number of significantly expressed
genes they contain and also list diseases that were most
significant. A network is a graphical representationFigure 1 Growth inhibitory effect of YM155 on SK-NEP-1 cells. (A) Mo
Sk-NEP-1 cells (2 × 104) were seeded in 96-well plates overnight and incub
(0.005, 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64or 1.28 μM) for 24 hours. Compar
was calculated from the absorbance values. Cell proliferation was calculate
derived after plotting proliferation values on a logarithmic curve. Experimeof the molecular relationships between molecules.
Molecules are represented as nodes, and the biological
relationship between two nodes is represented as an
edge (line). All edges are supported by at least 1 refer-
ence from the literature, from a textbook, or from
canonical information stored in the Ingenuity Pathways
Knowledge Base.
Statistical analysis
At least three replicates for each experimental condition
were performed, and the presented results were repre-
sentative of these replicates. All values are presented as
means ± SEM. Student’s paired t-test was applied to re-
veal statistical significances. P values less than 0.05 were
considered significant. Statistical analyses were per-
formed using SPSS Software for Windows (version 11.5;
SPSS, Inc., Chicago, IL).
Results
Growth inhibitory effect of YM155 on SK-NEP-1 cells
YM155 treatment resulted in inhibition of cell prolifera-
tion of SK-NEP-1cells in a dose-dependent manner
(Figure 1B). 93%, 85%, 70%, 55% and 30% cells were vi-
able when 10nM, 20nM, 40nM, 80nM and 160nM
YM155 treated 24 hours. So the IC50 of YM155 for SK-
NEP-1 cells was about 100nM. The adherence of SK-
NEP-1 cells was much inhibited by YM155-treatment.
YM155 induced detachment of the cells from the dishes
(Data not shown).
YM155 induced apoptosis in SK-NEP-1 cells
To confirm whether YM155 induces apoptosis in SK-
NEP-1 cells, we further investigated Annexin V assay,
cell cycle, and activation of caspase-3 in SK-NEP-1 cells
after YM155 treatment. The result showed that cells
treated with YM155 50nM and 100nM for 6 and
12 hours, much more cells showed apoptotic featurelecular Structure of YM155. (B) Proliferation and IC50 analysis of YM155.
ated with DMSO, 1 nM YM155, or increasing concentrations of YM155
ed with the control group, the relative survival rate of remained cells
d as a percentage of the DMSO treated control wells with IC50 values
nts were performed in quadruplicate and repeated two times.
Figure 2 YM155 induced apoptosis in SK-NEP-1 cells. YM155 induced apoptosis, DNA fragmentation and activation of caspase 3 in SK-NEP-1
cells. (A) Annexin V analysis showed the cells treated with YM155 50nM and 100nM for 6 and 12 hours, much more cells showed apoptotic
feature compared with control group. These analyses were repeated three times, and the apoptotic cells in 6 hours was YM155 50nM: 5.9%
±2.3%,YM155 100nM 42.4% ±8.9% compared to DMSO group: 1.5%±0.4%; apoptotic cells in 12 hours was YM155 50nM: 31.5% ±5.7%, YM155
100nM 45.1% ±11.3% compared to DMSO group 6.5% ±2.1%. (B) Cell cycle analysis the cells treated with YM155 after 12, 24 and 36 hours. As
expected, DNA fragmentation was observed after 12 hours treatment and increased in a time dependent manner. These analyses were repeated
three times, and the apoptotic cells in YM155 50nM group: 12 hours 8.7% ±1.4%, 24 hours 23.2% ±6.7%, 36 hours 74.0%±9.2%; apoptotic cells in
YM155 100nM group: 12 hours 18.5% ±3.7% , 24 hours 25.4% ±9.2% , 36 hours 60.9% ±14.2%. (C) Western-blot analysis the activation of caspase
3 in cells treated with YM155. After 6 and 12 hours treatment with 10nM, 50nM, 100nM and 200nM YM155, cleaved caspase-3 was observed.
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lyses were repeated three times, and the apoptotic cells
in 6 hours was YM155 50nM: 5.9% ±2.3%,YM155
100nM 42.4% ±8.9% compared to DMSO group: 1.5%
±0.4%; apoptotic cells in 12 hours was YM155 50nM:
31.5% ±5.7%, YM155 100nM 45.1% ±11.3% compared
to DMSO group 6.5% ±2.1%. Cell cycle was confirmed
by Cell cycle assay (Figure 2B). As expected, DNA frag-
mentation was observed after 12 hours treatment and
increased in a time dependent manner. These analyses
were repeated three times, and the apoptotic cells in
YM155 50nM group: 12 hours 8.7% ±1.4%, 24 hours
23.2% ±6.7%, 36 hours 74.0%±9.2%; apoptotic cells in
YM155 100nM group: 12 hours 18.5% ±3.7% , 24 hours
25.4% ±9.2% , 36 hours 60.9% ±14.2%. Moreover, to
clearly demonstrate that YM155 causes apoptosis in SK-
NEP-1 cells, we assessed the molecular aspects of apop-
tosis, caspase-3, well recognized as a marker of apoptosisFigure 3 YM155 treatment inhibited growth of SK-NEP-1 xenograft tu
five nude mice every group. 10 days after injection, mice were treated with
weeks these mice were examined for subcutaneous tumor growth. The tum
volume = length × width2/2. After the last treatment, the mice were killed
from the treatment experiment. (B) Growth curve of SK-NEP-1 cells treated
SK-NEP-1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm3; YM155 10 mg/kg: 0
PBS group cells (PBS: 3.78 ± 2.20 cm3, ANOVA P < 0.01). (C) Tumor weight
tumors (YM155 5 mg/kg: 1.05 ± 0.24 g; YM155 10 mg/kg: 0.72 ± 0.17 g) co
2.36 ± 0.43 g, ANOVA P < 0.01). (D) Body weight of nude mice in the treat
almost same with control group (YM155 5 mg/kg:20.12 ± 1.66 g; YM155 10
1.83 g) or PBS group cells (PBS: 20.66 ± 1.37 g, ANOVA P >0.05).by western blot. After 6 and 12 hours treatment with
10nM, 50nM, 100nM and 200nM YM155, cleaved
caspase-3 was observed (Figure 2C). This result is con-
sistent with the data of Annexin V assay and cell cycle
analysis, demonstrating that YM155 induced apoptosis
in SK-NEP-1 cells. The results from both studies suggest
that YM155 has promising antitumor activity against
SK-NEP-1 cells.
YM155 treatment inhibited growth of SK-NEP-1 xenograft
tumor in nude mice
We next assessed the impact of YM155 on the cell
growth of SK-NEP-1 cells in nude mice. SK-NEP-1 cells
were subcutaneously injected into five nude mice every
group. 10 days after injection, mice were treated with
PBS, DMSO, YM155 5 mg/kg and 10 mg/kg dose. Dur-
ing the next six weeks these mice were examined for
subcutaneous tumor growth. After the last treatment,mor in nude mice. SK-NEP-1 cells were subcutaneously injected into
PBS, DMSO, YM155 5 mg/kg and 10 mg/kg dose. During the next six
or volumes were calculated according to the following formula:
and the tumor weight was measured. (A) SK-NEP-1 xenograft tumors
with YM155, DMSO and PBS. YM155 significantly inhibited growth of
.95 ± 0.55 cm3) compared to DMSO group (DMSO: 3.70 ± 2.4 cm3) or
of the treatment experiment. YM155 treatment decreased weight of
mpared to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group cells (PBS:
ment experiment. Body weight of nude mice treated with YM155 was
mg/kg: 19.92 ± 1.72 g) compared to DMSO group (DMSO: 20.88 ±
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sured. YM155 significantly inhibited growth of SK-NEP-
1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm3; YM155
10 mg/kg: 0.95 ± 0.55 cm3) compared to DMSO group
(DMSO: 3.70 ± 2.4 cm3) or PBS group cells (PBS: 3.78 ±
2.20 cm3, ANOVA P < 0.01 Figure 3A, 3B). YM155
treatment decreased weight of tumors (YM155 5 mg/kg:
1.05 ± 0.24 g; YM155 10 mg/kg: 0.72 ± 0.17 g) compared
to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group
cells (PBS: 2.36 ± 0.43 g, ANOVA P < 0.01 Figure 3C).
We also observed that the body weight of nude mice
treated with YM155 was almost same with control group
(YM155 5 mg/kg:20.12 ± 1.66 g; YM155 10 mg/kg:Table 1 Genes up regulated in SK-NEP-1 cells treated with YM
Gene Symbol
1 TNF Tumor necrosis factor
2 FOXO1 Forkhead box O1
3 IER3 Immediate early response 3
4 PEA15 Phosphoprotein enriched in astrocytes 15
5 CD5 CD5 molecule
6 NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S prot
7 TNFAIP3 Tumor necrosis factor, alpha-induced prote
8 NFKB1 nuclear factor of kappa gene enhancer in B-c
9 CRYAB Crystallin, alpha B
10 DDIT3 DNA-damage-inducible transcript 3
11 CRADD CASP2 domain containing adaptor with death d
12 BNIP1 BCL2/adenovirus E1B 19 kDa interacting prote
13 BBC3 BCL2 binding component 3
14 NOX5 NADPH oxidase, EF-hand calcium binding dom
15 CASP7 Caspase 7, apoptosis-related cysteine peptid
16 PIM2 Pim-2 oncogene
17 CEBPG CCAAT/enhancer binding protein (C/EBP), gam
18 EDA Ectodysplasin A
19 SOCS2 Suppressor of cytokine signaling 2
20 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, C
21 IL1A Interleukin 1, alpha
22 BIRC8 Baculoviral IAP repeat containing 8
23 SERPINB2 Serpin peptidase inhibitor, clade B membe
24 CASP9 Caspase 9, apoptosis-related cysteine peptid
25 LTB Lymphotoxin beta (TNF superfamily, membe
26 PMAIP1 Phorbol-12-myristate-13-acetate-induced prot
27 NUPR1 Nuclear protein, transcriptional regulator,
28 BIRC3 Baculoviral IAP repeat containing 3
29 DIABLO IAP-binding mitochondrial protein
30 LTBR Lymphotoxin beta receptor
31 COL4A3 Collagen, type IV, alpha 3
32 FOXO3 Forkhead box O319.92 ± 1.72 g) compared to DMSO group (DMSO:
20.88 ± 1.83 g) or PBS group cells (PBS: 20.66 ± 1.37 g,
ANOVA P >0.05 Figure 3D). These studies support the
view that YM155 had significant role and little side ef-
fect in the treatment of SK-NEP-1 xenograft tumors.
Real-time PCR array analysis the dyes-regulated genes
implicated into YM155 treatment
In order to identify apoptosis and/or programmed
cell death molecules implicated into the treatment with
YM155, we used the SABioscience Human Apoptosis
PCR Array PAHS-3012.We analyzed and clustered the
expression of 370 key genes involved in apoptosis, or155 compared with DMSO control group
+DMSO +YM155 Ratio P value
0.052 3.274 62.850 0.0085
3.109 59.967 19.287 0.0091
53.221 795.891 14.955 0.0093
85.200 642.789 7.545 0.0105
0.079 0.584 7.405 0.0105
ein 3, 127.186 919.431 7.229 0.0106
in 3 69.132 449.671 6.505 0.0109
ells 1 58.200 377.771 6.491 0.0109
7.704 49.315 6.401 0.0109
134.710 768.681 5.706 0.0113
omain 10.127 56.007 5.531 0.0114
in 1 89.770 475.609 5.298 0.0115
1.388 6.896 4.969 0.0118
ain 5 0.213 1.057 4.953 0.0118
ase 20.274 95.136 4.693 0.0120
29.093 118.888 4.087 0.0127
ma 11.867 47.745 4.023 0.0128
0.710 2.846 4.009 0.0128
0.258 1.018 3.953 0.0129
ip1) 124.431 479.383 3.853 0.0131
146.968 423.629 2.882 0.0155
0.248 0.692 2.785 0.0159
r 2 0.136 0.362 2.659 0.0165
ase 330.442 853.550 2.583 0.0169
r 3) 0.052 0.134 2.580 0.0170
ein 1 258.441 642.950 2.488 0.0175
1 25.295 61.632 2.437 0.0179
97.141 232.642 2.395 0.0183
178.419 417.832 2.342 0.0187
120.546 280.744 2.329 0.0188
5.993 12.916 2.155 0.0208
34.671 71.488 2.062 0.0222
Table 2 Genes down regulated in SK-NEP-1 cells treated with YM155 compared with DMSO control group
Gene Symbol +DMSO +YM155 Ratio P value
1 HIPK2 Homeodomain interacting protein kinase 2 31.640 11.619 0.367 0.0353
2 CD27 CD27 molecule 1.462 0.538 0.368 0.0353
3 PCBP4 Poly(rC) binding protein 4 9.419 3.481 0.370 0.0334
4 PAK7 P21 protein (Cdc42/Rac)-activated kinase 7 0.120 0.044 0.370 0.0334
5 PPP1R13B Protein phosphatase 1, regulatory subunit 13B 75.280 27.926 0.371 0.0322
6 TP73 Tumor protein p73 9.738 3.619 0.372 0.0321
7 RASA1 RAS p21 protein activator 1 138.406 49.465 0.357 0.0315
8 CRYAA Crystallin, alpha A 0.210 0.079 0.375 0.0272
9 TIAF1 TGFB1-induced anti-apoptotic factor 1 243.057 91.076 0.375 0.0242
10 CARD14 Caspase recruitment domain family, member 14 37.791 13.412 0.355 0.0241
11 NOD1 Nucleotide-binding domain containing 1 163.081 61.858 0.379 0.0214
12 TNFRSF1B Tumor necrosis factor receptor superfamily 1B 45.110 17.323 0.384 0.0174
13 HIP1 Huntingtin interacting protein 1 14.568 4.941 0.339 0.0174
14 UTP11L UTP11-like, U3 small nucleolar ribonucleoprotein 267.624 104.245 0.390 0.0118
15 SPP1 Secreted phosphoprotein 1 2.389 0.801 0.335 0.0107
16 NME5 NME/NM23 family member 5 0.217 0.073 0.335 0.0092
17 MYO18A Myosin XVIIIA 164.894 54.821 0.332 0.0087
18 PPP2R1B Protein phosphatase 2, regulatory subunit A 9.768 3.887 0.398 0.0033
19 BAG1 BCL2-associated athanogene 70.273 28.001 0.398 0.0033
20 DAPK2 Death-associated protein kinase 2 1.549 0.509 0.329 0.0023
21 TNFSF10 Tumor necrosis factor (ligand) superfamily 10 2.596 0.844 0.325 0.0022
22 TNFRSF25 Tumor necrosis factor receptor superfamily 25 10.685 4.340 0.406 0.0022
23 FOXL2 Forkhead box L2 11.954 4.886 0.409 0.0021
24 CASP10 Caspase 10, apoptosis-related cysteine peptidase 13.465 4.252 0.316 0.0021
25 CARD8 Caspase recruitment domain family, member 8 3.835 1.209 0.315 0.0020
26 ALOX12 Arachidonate 12-lipoxygenase 9.725 3.039 0.312 0.0020
27 OPA1 Optic atrophy 1 (autosomal dominant) 172.500 71.720 0.416 0.0020
28 ERN2 Endoplasmic reticulum to nucleus signaling 2 2.851 1.187 0.416 0.0020
29 STK17A Serine/threonine kinase 17a 111.835 46.583 0.417 0.0020
30 CARD9 Caspase recruitment domain family, member 9 5.195 1.578 0.304 0.0020
31 GRM4 Glutamate receptor, metabotropic 4 0.958 0.408 0.426 0.0020
32 SON SON DNA binding protein 547.934 234.409 0.428 0.0019
33 PLAGL2 Pleiomorphic adenoma gene-like 2 69.972 30.027 0.429 0.0019
34 BIRC5 Baculoviral IAP repeat containing 5 59.315 25.502 0.430 0.0019
35 FADD Fas (TNFRSF6)-associated via death domain 323.082 93.703 0.290 0.0019
36 NAIP NLR family, apoptosis inhibitory protein 44.019 12.731 0.289 0.0008
37 BCL2 B-cell CLL/lymphoma 2 6.950 3.020 0.435 0.0008
38 ZNF443 Zinc finger protein 443 8.149 3.583 0.440 0.0003
39 CASP8AP2 Caspase 8 associated protein 2 43.673 19.445 0.445 0.0003
40 CUL5 Cullin 5 134.969 60.117 0.445 0.0002
41 DAPK1 Death-associated protein kinase 1 15.806 4.237 0.268 <0.0001
42 NKX3-2 NK3 homeobox 2 0.830 0.371 0.447 <0.0001
43 SEMA4D Itransmembrane domain semaphoring 4D 9.709 2.589 0.267 <0.0001
44 SST Somatostatin 0.694 0.179 0.258 <0.0001
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Table 2 Genes down regulated in SK-NEP-1 cells treated with YM155 compared with DMSO control group (Continued)
45 ALOX15B Arachidonate 15-lipoxygenase, type B 0.263 0.063 0.242 <0.0001
46 NOTCH2 Notch 2 930.886 223.933 0.241 <0.0001
47 NLRC4 NLR family, CARD domain containing 4 20.624 4.653 0.226 <0.0001
48 PRKCA Protein kinase C, alpha 30.560 6.439 0.211 <0.0001
49 APOE Apolipoprotein E 1.075 0.210 0.195 <0.0001
50 NTF3 Neurotrophin 3 0.295 0.044 0.150 <0.0001
51 CARD17 Caspase recruitment domain family, member 17 0.363 0.047 0.131 <0.0001
52 MAPK8IP2 Mitogen kinase 8 interacting protein 2 0.432 0.049 0.114 <0.0001
53 F2 coagulation factor II 3.794 0.104 0.027 <0.0001
54 CUL3 cullin 3 1.228 0.059 0.048 <0.0001
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http://www.biomedcentral.com/1471-2407/12/619programmed cell death with this PCR Array (Add-
itional file 1). This array includes the TNF ligands and
their receptors; members of the bcl-2 family, BIRC
(baculoviral IAP repeat) domain proteins, CARD do-
main (caspase recruitment domain) proteins, death do-
main proteins, TRAF (TNF receptor-associated factor)
domain proteins and caspases. We can easily and reli-
ably analyze the expression of a focused panel of genes
related to apoptosis with this array. Comparison of
PCR results between Test group and control group
showed that 32 genes were significantly up-regulated
and 54 genes were significantly down-regulated after
YM155 treatment (Table 1 and Table 2).
Ingenuity pathway analysis the pathway regulated by
YM155
To investigate possible biological interactions of differ-
ently regulated genes, datasets representing genes with
altered expression profile derived from real-time PCR
array analyses were imported into the Ingenuity Pathway
Analysis Tool. The list of differentially expressed genes
analyzed by IPA revealed significant networks. Figure 4A
represents the list of top 5 networks identified by IPA.
Of these networks, cell death was the highest rated net-
work with 65 focus molecules and the significance score
of 44 (Figure 4D). The score is the probability that a
collection of genes equal to or greater than the number
in a network could be achieved by chance alone. A score
of 3 indicates a 1/1000 chance that the focus genes are
in a network not due to random chance. The IPA ana-
lysis also groups the differentially expressed genes into
biological mechanisms that are related to cell death,
cellular function maintenance, cell morphology, carbo-
hydrate metabolism and cellular growth and prolifera-
tion (Figure 4B). Death receptor signaling (3.87E-19),
TNFR1 signaling (2.34E-13), induction of apoptosis
by HIV1 (2.67E-12), apoptosis signaling (6.56E-12) and
molecular mechanisms of cancer (2.13E-11) came out to
be the top four most significant pathways (Figure 4C).
IPA analysis also showed top molecules up-regulated wereBBC3,BIRC3,BIRC8,BNIP1,CASP7,CASP9,CD5,CDKN1A,
CEBPG and COL4A3, top molecules down-regulated
were ZNF443, UTP11L, TP73, TNFSF10, TNFRSF1B,
TNFRSF25,TIAF1,STK17A,SST and SPP1, upstream
regulator were NR3C1, TP53, dexamethasone , TNF
and Akt ( Additional file 2). These upstream regulators
such as TP53, TNF and Akt have already been reported
as important regulators for the surviving network.
TP53 and Akt have been widely investigated and there
are hundreds of papers about the important roles in
surviving pathway. But there is still no report about
the relationship between NR3C1, dexamethasone and
survivin.
This work indicated firstly that NR3C1and dexametha-
sone may be upstream regulators in the survivin path-
way. These results may provide new clues of molecular
mechanism of apoptosis induced by YM155.Discussion
Survivin is highly expressed in a broad range of solid
tumors and hematological malignancies. Increased survi-
vin expression in cancer patients is an unfavorable prog-
nostic marker correlating with decreased overall survival
in several malignancies, including non-small cell lung
[24-26], gastric [27-31], colorectal [32-34], and breast
carcinomas [35], neuroblastoma [36], prostate cancer
[37], pancreatic cancer [38] , hepatocellular carcinoma
[39] and hematologic malignancies [40-44]. Increased
survivin expression was also associated with increased
risk of recurrence, lymph node invasion and metastasis.
Finally, survivin overexpression may be a predictive fac-
tor to determine response to chemotherapy and radio-
therapy in patients with bladder cancer, breast cancer,
multiple myeloma and lymphoma. Studies have shown
that survivin suppression induces tumor cell apoptosis
and enhances sensitivity to apoptosis induced by existing
anticancer drugs and other apoptotic stimuli. This work
indicated that survivin also be an important target for
human Wilms tumor cells.
Figure 4 (See legend on next page.)
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Figure 4 Ingenuity Pathways Analysis (IPA) summary. To investigate possible interactions of differently regulated genes, datasets representing
86 genes with altered expression profile obtained from real-time PCR arrays were imported into the Ingenuity Pathway Analysis Tool and the
following data is illustrated: (A) The list of top five networks with their respective scores obtained from IPA . (B) The list of top five molecular and
cellular functions with their respective scores obtained from IPA. (C) Toxicology pathway list in IPA analysis. The x-axis represents the top
toxicology functions as calculated by IPA based on differentially expressed genes are highlighted and the y-axis represents the ratio of number of
genes from the dataset that map to the pathway and the number of all known genes ascribed to the pathway. The yellow line represents the
threshold of p value, 0.05 as calculated by Fischer’s test. (D) Most highly rated network in IPA analysis. The network representation of the most
highly rated network. The genes that are shaded were determined to be significant from the statistical analysis. A solid line represents a direct
interaction between the two gene products and a dotted line means there is an indirect interaction.
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in clinical development by Astellas Pharma, Inc. YM155
inhibited the growth of 119 human cancer cell lines,
with the greatest activity in lines derived from non-
Hodgkin’s lymphoma, hormone-refractory prostate can-
cer, ovarian cancer, sarcoma, non-small-cell lung cancer,
breast cancer, leukemia and melanoma. The mean log
growth inhibition of 50% (GI50) value was 15 nM. A
preclinical study showed that YM155 suppressed both
survivin protein and mRNA expression. In a toxicologic
study, short-term exposure at high blood concentrations
caused cardiotoxicity in the form of atrioventricular. In
this phase I study, YM155 seemed to be safe and well-
tolerated, with a maximum tolerated dose of 8.0 mg/m2/
d. Stable disease was achieved in nine patients. The data
in this study indicate that the adverse reactions observed
can be well-controlled by taking due caution and suggest
that YM155 has more easily controllable toxicities com-
pared with conventional cytotoxic anticancer drugs. This
work also supports the view that YM155 had significant
role and little side effect in the treatment of SK-NEP-1
xenograft tumors.
Real-time PCR Array System is the ideal tool for ana-
lyzing the expression of a focused panel of genes. The
flexibility, simplicity, and convenience of standard SYBR
Green PCR detection methodology make the PCR Array
System accessible for routine use in any research labora-
tory [45]. In this study, we analyzed the dyes-regulated
genes by YM155 with this powerful platform, Real-time
PCR arrays.
Comparison of PCR results between Test group and
control group showed that 32 genes were significantly
up-regulated and 54 genes were significantly down-
regulated after YM155 treatment. Some genes, such as
TNF, NFKB1, CDKN1A, CASP9, COL4A3, BIRC5 (sur-
vivin), BCL2, and DAPK1 have already been reported
with YM155 treatment. There are also some other genes
never reported with YM155 treatment and these genes
have complicate functions far exceeds the apoptosis.
These results consistent with the complicate roles of
survivin in cancer biology. Survivin has been implicated
in the regulation of the mitotic spindle checkpoint, from
kinetic core to spindle assembly; it’s over expression incancer may allow cells with spindle defects or misaligned
kinetic cores to continue through cell division. Recent
studies also suggest that survivin plays a role in tumor
progression and chemoresistance. Survivin has been
shown to inhibit cell death induced by several anticancer
agents, including paclitaxel [46], etoposide [47] and
Tumor Necrosis Factor-a related apoptosis-inducing lig-
and [47,48]. In vitro and in vivo studies showed that
inhibiting survivin reduces tumor growth potential and
sensitizes tumor cells to chemotherapeutic agents, such
paclitaxel, cisplatin [14,49], etoposide, gamma irradiation
and immunotherapy. To explore the molecule mechan-
ism of YM155 treatment, we try to explore new target
and “net work” of YM155 with a powerful platform, In-
genuity Pathway Analysis program.
The basis of the IPA program consists of the Ingenuity
Pathway Knowledge Base (IPKB) which is derived from
known functions and interactions of genes published in
the literature. The IPA Tool allows the identification of
biological networks, global functions and functional
pathways of a particular dataset. The program also gives
the significance value of the genes, the other genes with
which it interacts, and how the products of the genes
directly or indirectly act on each other, including those
not involved in the microarray analysis. This work repre-
sents cell death was the highest rated network with 65
focus molecules and the significance score of 44. Death
receptor signaling, TNFR1 signaling ,induction of apop-
tosis by HIV1 ,apoptosis signaling and molecular
mechanisms of cancer came out to be the top four most
significant pathways. IPA analysis also showed top mole-
cules up-regulated was BBC3 (PUMA). PUMA encodes
a member of the BCL-2 family of proteins. This family
member belongs to the BH3-only pro-apoptotic subclass. The
protein cooperates with direct activator proteins to induce
mitochondrial outer membrane permeabilization and apop-
tosis. It can bind to anti-apoptotic Bcl-2 family members to in-
duce mitochondrial dysfunction and caspase activation.
Because of its pro-apoptotic role, this gene is a potential drug
target for cancer therapy and for tissue injury. IPA analysis also
showed upstream regulators were NR3C1, TP53, dexametha-
sone, TNF and Akt. These upstream regulators such as TP53,
TNF and Akt have already been reported as important
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http://www.biomedcentral.com/1471-2407/12/619regulators for the survivin network. TP53 and Akt have been
widely investigated and there are hundreds of papers about
the important roles in survivin pathway. But there is still no
report about the relationship between NR3C1, dexamethasone
and survivin. NR3C1 gene encodes glucocorticoid receptor,
which can function both as a transcription factor that binds to
glucocorticoid response elements in the promoters of gluco-
corticoid responsive genes to activate their transcription and
as a regulator of other transcription factors. This receptor is
typically found in the cytoplasm, but upon ligand binding, is
transported into the nucleus. It is involved in inflammatory
responses, cellular proliferation, and differentiation in target
tissues. Dexamethasone gene encodes a member of the Ras
superfamily of small GTPases and is induced by dexametha-
sone. The encoded protein is an activator of G-protein signal-
ing and acts as a direct nucleotide exchange factor for Gi-Go
proteins. This protein interacts with the neuronal nitric oxide
adaptor protein CAPON, and a nuclear adaptor protein FE65,
which interacts with the Alzheimer's disease amyloid precur-
sor protein. This gene may play a role in dexamethasone-
induced alterations in cell morphology, growth and cell-
extracellular matrix interactions. Epigenetic inactivation of this
gene is closely correlated with resistance to dexamethasone in
multiple myeloma cells. This work indicated firstly that
NR3C1and dexamethasone may be upstream regulators in the
survivin pathway. These results may provide new clues of mo-
lecular mechanism of apoptosis induced by YM155.
Conclusions
The present study demonstrates that YM155 treatment
resulted in apoptosis and inhibition of cell proliferation
of SK-NEP-1cells. YM155 had significant role and little
side effect in the treatment of SK-NEP-1 xenograft
tumors. Real-time PCR array analysis firstly showed ex-
pression profile of genes dyes-regulated after YM155
treatment. IPA analysis also represents new molecule
mechanism of YM155 treatment, such as NR3C1 and
dexamethasone may be new target of YM155. And our
results may provide new clues of molecular mechanism
of apoptosis induced by YM155.
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